-
Je něco špatně v tomto záznamu ?
Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study
T. Krechler, M. Jáchymová, M. Pavlíková, M. Vecka, M. Zeman, Z. Krška, T. Švestka, A. Žák
Jazyk angličtina Země Slovensko
Grantová podpora
NR9528
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
- MeSH
- diabetes mellitus 2. typu genetika komplikace MeSH
- financování organizované MeSH
- genetická predispozice k nemoci MeSH
- inzulin genetika MeSH
- jednonukleotidový polymorfismus genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- minisatelitní repetice genetika MeSH
- nádory slinivky břišní genetika komplikace patologie MeSH
- pilotní projekty MeSH
- polymerázová řetězová reakce MeSH
- polymorfismus délky restrikčních fragmentů MeSH
- promotorové oblasti (genetika) genetika MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
Pancreatic cancer (PC) is one of the most frequent gastrointestinal malignancies with extremely poor prognosis. In spite of a relative low incidence of PC, in comparison with other cancers, PC is the fourth leading cause of cancer death in USA in both sexes. The available data clearly suggest that diabetes mellitus (DM) can be both a long-standing cause of PC and an early manifestation of the disease. Besides of DM, insulin resistance and high insulin levels are linked as well with increased cancer risk, including PC. The variable number of tandem repeats (VNTR) locus upstream of the insulin gene (INS) regulates insulin expression and has been associated with susceptibility to many diseases including DM. It is known that there is nearly complete linkage disequilibrium of the insulin variable tandem of repeats (INS-VNTR) alleles I/III with neighboring -23 HphI A/T single nucleotide polymorphism (SNP) in Caucasians. Therefore, we have studied the association between SNP of -23HphI in promoter of INS with PC, DM Type 2 (2TDM) and healthy controls. In this study we investigated 153 subjects (86 M/67 F); 51 patients with newly-diagnosed PC (31 M/20 F), 45 patients with 2TDM (29 M/16 F) and 57 healthy control subjects (26 M/31 F). The polymorphism of -23HphI (A/T) in the promoter of INS was determined by the combination of polymerase chain reaction (PCR) with the restriction fragment length polymorphism (RFLP) methods. The results obtained by the PCR-RFLP analyses of SNP -23HphI were confirmed by a direct studied locus sequencing of the genomic DNA. The frequency of abnormal glucose metabolism (both DM and impaired fasting glucose) was 88 % (45/51) in PC group. The AA genotype in SNP -23HphI was more prevalent (67 % vs. 47 %; P<0.05) among PC patients compared to controls. Additionally, statistically significant differences were found in frequencies (%) of genotypes AA/AT/TT in groups with PC (67/27/6), 2TDM (53/40/7) compared to healthy controls (37/46/17) (P<0.05). Moreover, a statistically significant effect of -23HphI A/T polymorphism on tumor staging was found (P< 0.05). Polymorphism of -23HphI (A/T) in the promoter of INS may play a role in the pathogenesis of PC and could contribute to tumor staging. Key words: pancreatic cancer; insulin gene regulation; polymorphism of -23HphI; diabetes mellitus; disorders of glucoregulation.
- 000
- 04290naa 2200517 a 4500
- 001
- bmc11009854
- 003
- CZ-PrNML
- 005
- 20140320124532.0
- 008
- 110511s2009 xo e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Krechler, Tomáš $7 xx0083600
- 245 10
- $a Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study / $c T. Krechler, M. Jáchymová, M. Pavlíková, M. Vecka, M. Zeman, Z. Krška, T. Švestka, A. Žák
- 314 __
- $a 4th Department of Medicine, 1st Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic. krechler@vfn.cz
- 520 9_
- $a Pancreatic cancer (PC) is one of the most frequent gastrointestinal malignancies with extremely poor prognosis. In spite of a relative low incidence of PC, in comparison with other cancers, PC is the fourth leading cause of cancer death in USA in both sexes. The available data clearly suggest that diabetes mellitus (DM) can be both a long-standing cause of PC and an early manifestation of the disease. Besides of DM, insulin resistance and high insulin levels are linked as well with increased cancer risk, including PC. The variable number of tandem repeats (VNTR) locus upstream of the insulin gene (INS) regulates insulin expression and has been associated with susceptibility to many diseases including DM. It is known that there is nearly complete linkage disequilibrium of the insulin variable tandem of repeats (INS-VNTR) alleles I/III with neighboring -23 HphI A/T single nucleotide polymorphism (SNP) in Caucasians. Therefore, we have studied the association between SNP of -23HphI in promoter of INS with PC, DM Type 2 (2TDM) and healthy controls. In this study we investigated 153 subjects (86 M/67 F); 51 patients with newly-diagnosed PC (31 M/20 F), 45 patients with 2TDM (29 M/16 F) and 57 healthy control subjects (26 M/31 F). The polymorphism of -23HphI (A/T) in the promoter of INS was determined by the combination of polymerase chain reaction (PCR) with the restriction fragment length polymorphism (RFLP) methods. The results obtained by the PCR-RFLP analyses of SNP -23HphI were confirmed by a direct studied locus sequencing of the genomic DNA. The frequency of abnormal glucose metabolism (both DM and impaired fasting glucose) was 88 % (45/51) in PC group. The AA genotype in SNP -23HphI was more prevalent (67 % vs. 47 %; P<0.05) among PC patients compared to controls. Additionally, statistically significant differences were found in frequencies (%) of genotypes AA/AT/TT in groups with PC (67/27/6), 2TDM (53/40/7) compared to healthy controls (37/46/17) (P<0.05). Moreover, a statistically significant effect of -23HphI A/T polymorphism on tumor staging was found (P< 0.05). Polymorphism of -23HphI (A/T) in the promoter of INS may play a role in the pathogenesis of PC and could contribute to tumor staging. Key words: pancreatic cancer; insulin gene regulation; polymorphism of -23HphI; diabetes mellitus; disorders of glucoregulation.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a diabetes mellitus 2. typu $x genetika $x komplikace $7 D003924
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inzulin $x genetika $7 D007328
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a minisatelitní repetice $x genetika $7 D018598
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a nádory slinivky břišní $x genetika $x komplikace $x patologie $7 D010190
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a polymerázová řetězová reakce $7 D016133
- 650 _2
- $a polymorfismus délky restrikčních fragmentů $7 D012150
- 650 _2
- $a jednonukleotidový polymorfismus $x genetika $7 D020641
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Jáchymová, Marie $7 xx0072686
- 700 1_
- $a Pavlíková, Markéta, $d 1975- $7 xx0093283
- 700 1_
- $a Vecka, Marek, $d 1976- $7 xx0076497
- 700 1_
- $a Zeman, Miroslav, $d 1950- $7 skuk0006053
- 700 1_
- $a Krška, Zdeněk, $d 1958- $7 jn19990209431
- 700 1_
- $a Švestka, Tomislav $7 nlk20010094488
- 700 1_
- $a Žák, Aleš, $d 1951- $7 mzk2007382175
- 773 0_
- $t Neoplasma $w MED00003470 $g Roč. 56, č. 1 (2009), s. 26-32 $x 0028-2685
- 910 __
- $a ABA008 $b A 1194 $y 2 $z 0
- 990 __
- $a 20110513111323 $b ABA008
- 991 __
- $a 20140320124559 $b ABA008
- 999 __
- $a ok $b bmc $g 839179 $s 703255
- BAS __
- $a 3
- BMC __
- $a 2009 $b 56 $c 1 $d 26-32 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- GRA __
- $a NR9528 $p MZ0
- LZP __
- $a 2011-2B09/jvme